Posted by Michael Wonder on 23 May 2023
US FDA approves the Cyltezo Pen, a new auto-injector option, ahead of 1 July commercial launch
22 May 2023 - Cyltezo (adalimumab-adbm) will be commercially available in the US beginning on 1 July 2023.
Boehringer Ingelheim announced today that the US FDA has approved the Cyltezo Pen, a new auto-injector option for Cyltezo (adalimumab-adbm), an FDA approved Interchangeable biosimilar to Humira (adalimumab).
Initially approved as a pre-filled syringe, Cyltezo is indicated to treat multiple chronic inflammatory diseases. The 40 mg/0.8 mL pre-filled Cyltezo Pen will be available in two-, four- and six-pack options on 1 July 2023.
